Cited by 127Diabetes Treatment and ManagementPeroxisome Proliferator-Activated ReceptorsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Rosiglitazone and cardiotoxicity –weighing the evidence

Open access

Nathan, David M.·2007·New England Journal of Medicine

DOI 10.1056/nejme078117

Open this paper in CoChat — free account Open PDF

Abstract

The recently published meta-analysis by Nissen and Wolski,1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar magnitude, albeit nonsignificant, in the risk of death from cardiovascular causes, has created a furor in the press and a quandary for physicians and their patients. Given the vagaries of meta-analyses in general and of this meta-analysis in particular — owing to the absence of primary or time-to-event data, as acknowledged both in the article and in the accompanying editorial2 — clinicians have been left uncertain as to whether rosiglitazone . . .

Integrity signals

Registry

Crossref · 10.1056/nejme078117

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
Choi, D., Kim, S., Choi, S. H., Ko, Y., Ahn, C. W., Jang, Y., Lim, S.-K., Lee, H., & Soo, B. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2654 · Cited by 243
Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068294 · Cited by 216
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 179
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
Home, P. D., Pocock, S., Beck‐Nielsen, H., Gomis, R., Markolf Hanefeld, E., Dargie, H., Michel Komajda, N., Gubb, J., Biswas, N., & Jones, N. P. (2005) · Diabetologia · doi:10.1007/s00125-005-1869-1 · Cited by 149
Rosiglitazone RECORD study: glucose control outcomes at 18 months
Home, P., Jones, N. P., Pocock, S., Beck‐Nielsen, H., Gomis, R., Markolf Hanefeld, E., Michel Komajda, N., Curtis, P. S., & for the RECORD Study Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02160.x · Cited by 82

Show all 10 references

Research works printed but not linked: 1

10.1056/NEJMoa073394 · DOI · Paper page

Sorted by citations

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citation
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,205
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Self-citation
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 324
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study
Sharma, M., Nazareth, I., & Petersen, I. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010210 · Cited by 291
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
Diamond, G. A., Bax, L., & Kaul, S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00182 · Cited by 288
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285
“However, they have concerning side effects including edema, congestive heart failure, and in the case of rosiglita-zone, myocardial infarction [66], which led to a black box warning from the Food and Drug Administration [67].”
Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target Effects
Abassi, Y. A., Xi, B., Zhang, W., Ye, P., Kirstein, S. L., Gaylord, M. R., Feinstein, S. C., Wang, X., & Xu, X. Y. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.011 · Cited by 254
Patient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 251
Metabolic syndrome and liver transplantation: A review and guide to management
Watt, K. D. S., & Charlton, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.040 · Cited by 246
Adiposity, Type 2 Diabetes, and Alzheimer's Disease
Luchsinger, J. A., & Gustafson, D. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1022 · Cited by 221
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan, D. M. (2009) · Diabetes Care · doi:10.2337/dc09-0271 · Cited by 207
Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease
Luchsinger, J. A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.048 · Cited by 171
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan, D. M. (2009) · Diabetes Care · doi:10.2337/dc08-2195 · Cited by 170
Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese
Tan, C. Y., & Vidal‐Puig, A. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360935 · Cited by 169
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J. D., Devchand, P. R., Francis, S. A., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F. J., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 153
Photoacoustic molecular imaging-escorted adipose photodynamic–browning synergy for fighting obesity with virus-like complexes
Chen, R., Huang, S., Lin, T., Ma, H., Shan, W., Duan, F., Lv, J., Zhang, J., Ren, L., & Nie, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00844-6 · Cited by 154
Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal
Dunaif, A. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0787 · Cited by 122
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 120
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. S., & Zinman, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0873-z · Cited by 110
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs
Binda, C., Aldeco, M., Geldenhuys, W. J., Tortorici, M., Mattevi, A., & Edmondson, D. E. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200196p · Cited by 100
Structural insight into function and regulation of carnitine palmitoyltransferase
Rufer, A. C., Thoma, R., & Hennig, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0035-1 · Cited by 96
Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Girnun, G. D., Chen, L., Silvaggi, J. M., Drapkin, R., Chirieac, L. R., Padera, R. F., Upadhyay, R., Vafai, S. B., Weissleder, R., Mahmood, U., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1128 · Cited by 86
Rosiglitazone: a European regulatory perspective
BLIND, E., Dunder, K., de Graeff, P. A., & Abadie, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1992-5 · Cited by 70
Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 65
Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management
Rafiq, N., & Younossi, Z. M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.02.009 · Cited by 62
Insulin signaling
Coward, R. J., & Fornoni, A. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000078 · Cited by 63
Tamiflu and neuropsychiatric disturbance in adolescents
Maxwell, S. R. J. (2007) · BMJ · doi:10.1136/bmj.39240.497025.80 · Cited by 61
Insulin mediated novel therapies for the treatment of Alzheimer's disease
Dubey, S. K., Lakshmi, K. K., Krishna, K. V., Agrawal, M., Singhvi, G., Saha, R. N., Saraf, S., Saraf, S., Shukla, R., & Alexander, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117540 · Cited by 62
Frequency of HbA1c discordance in estimating blood glucose control
Cohen, R. M., & Smith, E. P. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32830467bd · Cited by 58
Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes
Ambrosius, W. T. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.310 · Cited by 56
Rosiglitazone — Continued Uncertainty about Safety
Drazen, J. M., Morrissey, S., & Curfman, G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078118 · Cited by 56
Drug-induced cardiac toxicity and adverse drug reactions, a narrative review
Destère, A., Merino, D., Lavrut, T., Rocher, F., Viard, D., Drici, M., & Gérard, A. O. (2023) · Therapies · doi:10.1016/j.therap.2023.10.008 · Cited by 61
The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels, K. B., & van Grootheest, K. (2012) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2012-0559 · Cited by 47
Rosiglitazone
Deeks, E. D., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767180-00008 · Cited by 43
Balancing Risk and Benefit with Oral Hypoglycemic Drugs
Hamnvik, O. R., & McMahon, G. T. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20116 · Cited by 44
Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat
Raso, G. M., Esposito, E., Iacono, A., Pacilio, M., Cuzzocrea, S., Canani, R. B., Calignano, A., & Meli, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.013 · Cited by 41
Setting the RECORD Straight
Nissen, S. E. (2010) · JAMA · doi:10.1001/jama.2010.333 · Cited by 41
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone
Hernández, A. V., Walker, E., Ioannidis, J. P. A., & Kattan, M. W. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.002 · Cited by 39
Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Erdmann, E., Charbonnel, B. H., & Wilcox, R. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970333 · Cited by 39
Projecting future drug expenditures—2008
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., & Schumock, G. T. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070629 · Cited by 38
Diagnosis of peripheral arterial disease of the lower limb
Bradbury, A. W., & Adam, D. J. (2007) · BMJ · doi:10.1136/bmj.39244.344664.80 · Cited by 37
Wpływ długotrwałego stosowania rozyglitazonu na zdarzenia sercowo-naczyniowe — przegląd systematyczny i metaanaliza
Cheng, D., Gao, H. T., & Li, W. (2018) · Endokrynologia Polska · doi:10.5603/ep.a2018.0036 · Cited by 43
Safety and Efficacy of D-Tagatose in Glycemic Control in Subjects with Type 2 Diabetes.
Ensor, M., Banfield, A., Smith, R. R., Williams, J., & Lodder, R. A. (2015) · PubMed · Cited by 33
Effects of Three Low-Doses of D-Tagatose on Glycemic Control Over Six Months in Subjects with Mild Type 2 Diabetes Mellitus Under Control with Diet and Exercise.
Ensor, M., Williams, J., Smith, R., Banfield, A., & Lodder, R. A. (2014) · PubMed · Cited by 30
Immunosuppression in cardiac graft rejection: A human in vitro model to study the potential use of new immunomodulatory drugs
Crescioli, C., Squecco, R., Cosmi, L., Sottili, M., Gelmini, S., Borgogni, E., Sarchielli, E., Scolletta, S., Francini, F., Annunziato, F., et al. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.016 · Cited by 29
Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study
Pisano, G., Fracanzani, A. L., Caccamo, L., Donato, M. F., & Fargion, S. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i40.8869 · Cited by 28
Dispensing patterns and financial costs of glucose‐lowering therapies in the UK from 2000 to 2008*
Currie, C. J., Peters, J. R., & Evans, M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02849.x · Cited by 27
Mitochondrial Dysfunction as a Mechanism for Pioglitazone-Induced Injury toward HepG2 Cell Line
Niknahad, H., Heidari, R., Alzuhairi, A. M., & Najibi, A. (2014) · Pharmaceutical Sciences · Cited by 26
Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study
SIMONE, G. D., Devereux, R. B., Roman, M. J., Chinali, M., Barac, A., Panza, J. A., Lee, E. T., Galloway, J. M., & Howard, B. V. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.06.007 · Cited by 24
Rosiglitazone treatment and cardiovascular disease in the V eterans A ffairs D iabetes Trial
Florez, H. J., Reaven, P. D., Bahn, G., MORITZ, T. E., Warren, S., Marks, J., Reda, D. J., Duckworth, W. C., Abraira, C., Hayward, R. A., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12487 · Cited by 21
Meta-analysis
Lee, J. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.6.361 · Cited by 21
Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone
Mendes, D., Alves, C., & Marques, F. B. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3874 · Cited by 20
Vascular disease and cognitive impairment
Reitz, C., Luchsinger, J. A., & Mayeux, R. P. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.8.1171 · Cited by 20
Posttransplant metabolic syndrome
Satapathy, S. K., & Charlton, M. (2010) · Liver Transplantation · doi:10.1002/lt.22222 · Cited by 19
Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications
Stockl, K. M., Le, L. B., Zhang, S., & Harada, A. S. M. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1700 · Cited by 19
Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective
Cubbon, R. M., Kahn, M., & Kearney, M. T. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01646.x · Cited by 18
Rosiglitazone and implications for pharmacovigilance
Kazi, D. S. (2007) · BMJ · doi:10.1136/bmj.39245.502546.be · Cited by 18
Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Sookoian, S. C., & Pirola, C. J. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082702 · Cited by 16
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis
Kabel, A. M., Elmaaboud, M. A. A., & Albarraq, A. A. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.12.003 · Cited by 16
Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus
Hennekens, C. H., Hebert, P. R., Schneider, W. R., O'Brien, P., DeMets, D. L., & BORER, J. S. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.06.001 · Cited by 16
Cardiovascular risk of rosiglitazone: another perspective
Waksman, J. C. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.12.0002 · Cited by 16
Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects.
Marchesi, C., & Schiffrin, E. (2008) · Journal of the American Society of Hypertension : JASH · doi:10.1016/j.jash.2007.12.007 · Cited by 17
Lessons From the Avandia Controversy
Misbin, R. I. (2007) · Diabetes Care · doi:10.2337/dc07-1908 · Cited by 15
Thiazolidinediones abrogate cervical cancer growth
Wuertz, B. R. K., Darrah, L., Wudel, J., & Ondrey, F. G. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.020 · Cited by 14
Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents.
Shaya, F. T., Lu, K., Sohn, K., & Weir, M. R. (2009) · Europe PMC (PubMed Central) · Cited by 14
Provision of primary care in different countries
Campbell, J. L. (2007) · BMJ · doi:10.1136/bmj.39237.534560.80 · Cited by 13
The PPARΩPocket: Renewed Opportunities for Drug Development
Kaupang, Å., & Hansen, T. V. (2020) · PPAR Research · doi:10.1155/2020/9657380 · Cited by 13
[Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes].
Shimizu, T., Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2012) · PubMed · Cited by 13
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Boccara, F., Dent, R. E., Ruilope, L. M., & Valensi, P. E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0586-8 · Cited by 14
Risk communication: the Avandia case, a pilot study
Löfstedt, R. E. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.49 · Cited by 12
Diabetic dyslipidemia and the metabolic syndrome
Cefalu, W. T. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2008.04.001 · Cited by 12
Antitumor activity of a novel series of α-aryloxy-α-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines
Xiong, X., Ye, Y., Fu, L., Dai, B., Liu, J., Jia, J., Tang, J., Lin, L., Wang, L., Shen, J., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9161-0 · Cited by 11
Seeking Alternatives to Hard End Points
Finn, A. V., Chandrashekhar, Y., & Narula, J. (2010) · Circulation · doi:10.1161/cir.0b013e3181d83b4f · Cited by 11
Therapeutic agents for Alzheimer’s disease: a critical appraisal
Weinstock, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1484615 · Cited by 9
Rosiglitazone and myocardial infarction: cause for concern or misleading meta‐analysis?
Bilous, R. W. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02259.x · Cited by 9
Glycemic Management of Type 2 Diabetes
Nathan, D. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2064 · Cited by 9
PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
Perreault, M., Erbe, D. V., & Tobin, J. F. (2008) · PPAR Research · doi:10.1155/2008/125387 · Cited by 9
Toxicological evaluation of subchronic use of pioglitazone in mice.
Elshama, S. S., El-Kenawy, A. E.-M., & Osman, H.-E. H. (2016) · PubMed Central · Cited by 7
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling
Liu, M., Fu, L., Liu, C., Xiong, X., Gao, X., Xiao, M., Cai, H., Hu, H., Wang, X., & Mei, C. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9313-x · Cited by 6
The effect of antidiabetic drugs on genes regulating lipid metabolism
TOMKIN, G. H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831ac56c · Cited by 6
In situ monitoring of mitochondrial redox dynamics during cardiac reprogramming using a poly-l-lysine/Matrigel-coated gold nanostructured composite platform
Koo, K., Seo, S. J., Kim, C., Yang, H., Jin, Y., & Kim, T. H. (2025) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-025-01331-z · Cited by 5
Type 2 Diabetes, Related Conditions, and Dementia
Luchsinger, J. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-850-8_13 · Cited by 5
Les stéatopathies métaboliques : conséquences hépatiques du syndrome métabolique
Anty, R., Gual, P., Huet, P., MARCHAND‐BRUSTEL, Y. L., & Tran, A. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)78350-1 · Cited by 5
Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract
Mayer, M. G. (2015) · F1000Research · doi:10.12688/f1000research.6878.1 · Cited by 4
Protective effects of Lagerstroemia speciosa on 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in HIT-T15 pancreatic β cells
Song, J., Zhao, X., Wang, Q., & ZHANG, T. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1396 · Cited by 4
Genotoxic properties of hypoglycemic drugs (systematic review)
Eremina, N. V., Жанатаев, А. К., Lisitsyn, A. A., & Durnev, A. D. (2021) · Ecological genetics · doi:10.17816/ecogen70691 · Cited by 4
Fractures, heart failure and fears of myocardial ischaemia: has the RECORD stuck for rosiglitazone and the thiazolidinediones?
Drummond, R. S., & Fisher, M. (2007) · Practical Diabetes · doi:10.1002/pdi.1133 · Cited by 4
Does rosiglitazone increase cardiovascular outcomes?
Doggrell, S. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2665 · Cited by 4
The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer’s Disease: An Epidemiological Perspective
Luchsinger, J. A. (2010) · Research and Perspectives in Alzheimer's Disease · doi:10.1007/978-3-642-04300-0_7 · Cited by 3
Putting the RECORD straight?
SADIKOT, S. M. (2009) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2009.07.014 · Cited by 3
The Rosiglitazone Controversy: Meta‐Analysis and the RECORD Study
Liebson, P. R. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.06099.x · Cited by 3
Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes
Fisher, M. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02150.x · Cited by 3
The rosiglitazone controversy: the Indian perspective.
Mohan, V., & Joshi, S. (2007) · PubMed · Cited by 3
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents
Xiong, X., Wang, L., Ye, Y., Fu, L., Chen, M., Wang, Q., Liu, M., Tang, J., Dai, B., Shen, J., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9278-9 · Cited by 2
The Rise and Fall of Rosiglitazone
Tatti, P. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2368 · Cited by 2
Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults
Braun, W. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50091-5 · Cited by 2
Thiazolidinediones and cardiovascular risk: Will the evidence so far available modify treatment strategies for type 2 diabetes?
Vaccaro, O., & Riccardi, G. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.01.003 · Cited by 2

Authors: Nathan, D. M.
Affiliations: Harvard University (US)
Corresponding author: Nathan, David M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-07-05
Volume: 357
Issue: 1
Pages: 64-66
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejme078117
OpenAlex: W2008001887
Cited by: 126
References: 10
Citations by year: 2025: 1 · 2024: 3 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 1 · 2012: 2
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: rosiglitazone, cardiotoxicity, myocardial infarction risk, cardiovascular mortality, meta-analysis critique, time-to-event data, thiazolidinediones, type 2 diabetes
MeSH terms: Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Heart Failure, Humans, Hypoglycemic Agents, Metformin, Sulfonylurea Compounds, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rosiglitazone and cardiotoxicity –weighing the evidence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks